Kaletra Tablets Offer Convenience Benefits, Abbott Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm plans to transition all patients on Kaletra (lopinavir/ritonavir) capsules to the new tablet formulation, which reduces the pill count and eliminates the need for refrigeration.
You may also be interested in...
Abbott's HIV Therapy Kaletra Gets Once-Daily Dosing
A once-daily dosing regimen of 800 mg lopinavir/200 mg ritonavir for treatment-naïve patients is approved based on two clinical trials comparing once- and twice-daily regimens in HIV-1 infected patients. Once-daily administration is not recommended for treatment-experienced patients, labeling states.
Madrigal’s FDA Approval In MASH Ends Years Of Industry Frustration
As the first approved MASH (formerly NASH) therapy, nearly four years after initially anticipated, Madrigal gets the opportunity to establish a MASH marketplace with Rezdiffra (resmetirom).
No More NASHing Of Teeth: Madrigal’s Resmetirom Approval Ends Years Of Industry Frustration
US FDA clears first MASH (formerly NASH) therapy, nearly four years after one had been initially anticipated. With the accelerated approval path established, Madrigal gets the opportunity to create a marketplace with Rezdiffra (resmetirom), and candidates in the pipeline get a clear target.